TP53 and hepatocellular carcinoma: A central finding of this study is the demonstration that the treatment of rats undergoing liver carcinogenesis with tributyrin during the promotion stage of the hepatocarcinogenic process, and rat and human HCC cells with sodium butyrate reduced the binding interaction between CRM1 and p53.